Choi Heekyoung, Jeong Su Jin, Lee Han Sung, Chin Bum Sik, Choi Suk Hoon, Han Sang Hoon, Kim Myung Soo, Kim Chang Oh, Choi Jun Yong, Song Young Goo, Kim June Myung
Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea.
J Korean Med Sci. 2008 Aug;23(4):737-9. doi: 10.3346/jkms.2008.23.4.737.
The combination of atazanavir (ATV) and lopinavir/ritonavir (LPV/RTV) with nucleoside reverse transcriptase inhibitors (NRTI) has been used as a salvage regimen for human immunodeficiency virus (HIV)-positive patients. In this paper, we discuss two cases of HIV-positive patients who had long histories of virological failure following a heavy treatment of antiretroviral drugs, but then achieved virological suppression with double-boosted protease inhibitor (PI) regimens. In patients with multiple genotypic resistance to PIs and NRTIs, virological suppression can be achieved with a combination of ATV plus LPV/RTV with an NRTI backbone. The two cases in this report suggest that a combination of ATV plus LPV/RTV could be a useful salvage regimen for the subset of HIV-positive patients with limited treatment options.
阿扎那韦(ATV)与洛匹那韦/利托那韦(LPV/RTV)联合核苷类逆转录酶抑制剂(NRTI)已被用作人类免疫缺陷病毒(HIV)阳性患者的挽救治疗方案。在本文中,我们讨论了两例HIV阳性患者,他们在接受大量抗逆转录病毒药物治疗后有长期病毒学失败史,但随后通过双重增强蛋白酶抑制剂(PI)方案实现了病毒学抑制。对于对PI和NRTI具有多重基因型耐药性的患者,ATV加LPV/RTV与NRTI主干药物联合使用可实现病毒学抑制。本报告中的两例病例表明,ATV加LPV/RTV联合方案可能是治疗选择有限的HIV阳性患者亚组的一种有用的挽救治疗方案。